



BeyondSpring Granted Approval to Start China Trials of Plinabulin

publication date: Jul 7, 2017

BeyondSpring, a New York City immuno-oncology company, received CFDA approval for two China Phase II/III trials of its lead molecule, plinabulin, as a treatment for neutropenia. One will be conducted in cancer patients being treated with docetaxel and another as an adjunct to a TAC regimen. An IV drug, plinabulin can be administered one hour after chemotherapy unlike the current standard of care, G-CSF, which requires a next-day visit to the hospital for infusion and, as a biologic drug, is more expensive. More details....

Stock Symbol: (NSDQ: BYSI)

<http://www.chinabiotoday.com/articles/20170707>